CESSA Stock Overview
Engages in identifying and developing drugs for the treatment of medical unmet need in children in Denmark.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Cessatech A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 8.00 |
| 52 Week High | DKK 8.10 |
| 52 Week Low | DKK 1.71 |
| Beta | 0.054 |
| 11 Month Change | 26.18% |
| 3 Month Change | 30.72% |
| 1 Year Change | 327.81% |
| 33 Year Change | -61.90% |
| 5 Year Change | n/a |
| Change since IPO | -31.62% |
Recent News & Updates
Shareholder Returns
| CESSA | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 12.0% | -1.8% | -4.2% |
| 1Y | 327.8% | 73.0% | 12.5% |
Return vs Industry: CESSA exceeded the Swedish Pharmaceuticals industry which returned 82.3% over the past year.
Return vs Market: CESSA exceeded the Swedish Market which returned 17% over the past year.
Price Volatility
| CESSA volatility | |
|---|---|
| CESSA Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 10.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: CESSA's share price has been volatile over the past 3 months.
Volatility Over Time: CESSA's weekly volatility has decreased from 13% to 5% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 4 | Jes Trygved | www.cessatech.com |
Cessatech A/S engages in identifying and developing drugs for the treatment of medical unmet need in children in Denmark. The company’s lead product is CT001, an analgesic nasal spray for the treatment of acute and planned painful procedures in children. It also develops CT002, a nasal spray for magnetic resonance imaging scanning; and CT003, a local anesthetic gel.
Cessatech A/S Fundamentals Summary
| CESSA fundamental statistics | |
|---|---|
| Market cap | DKK 139.40m |
| Earnings (TTM) | -DKK 24.87m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.6x
P/E RatioIs CESSA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CESSA income statement (TTM) | |
|---|---|
| Revenue | DKK 0 |
| Cost of Revenue | DKK 0 |
| Gross Profit | DKK 0 |
| Other Expenses | DKK 24.87m |
| Earnings | -DKK 24.87m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 21, 2024
| Earnings per share (EPS) | -1.43 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CESSA perform over the long term?
See historical performance and comparison